Loading company…
Stockholm-based specialty pharmaceutical company developing diagnostics and treatments for allergies in dogs, cats and horses.
Nextmune AB, founded in 2016 and headquartered in Stockholm, Sweden, develops diagnostic tools and prescription and non-prescription products for allergies and dermatological conditions in dogs, cats and horses. Its clients are veterinarians and pet owners in more than 70 countries. Fidelio Capital acquired the company in 2015 with terms undisclosed, and Bram Schuit and Vicente Leon serve as CEOs. In 2023 it reported revenue of USD 2.99 mn and EBITDA of USD 95,465.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in